Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19COVID-19로 입원하지 않은 성인을 대상으로 한 무작위 시험에서 밤라니비맙의 항바이러스 및 임상 활성Randomized Controlled Trial Published on 2022-08-222022-09-11 Journal: Nature Communications [Category] SARS, 바이오마커, 변종, 임상, 진단, 치료기술, 치료법, 치료제, [키워드] 1:1 adverse events Antiviral bamlanivimab clinical activity Clinical efficacy COVID-19 symptom COVID-19 symptoms COVID-19 therapeutics evaluated Evidence evidence of faster Inflammatory marker inflammatory markers median modeling monoclonal antibodies monoclonal antibody nasopharyngeal nasopharyngeal viral no differences Placebo Primary outcomes proportion provide Randomized Randomized controlled trial randomized trial reductions in risk risk ratio Safety SARS-CoV-2 RNA Symptom symptom duration undetectable variants of SARS-CoV-2 Viral with COVID-19 [DOI] 10.1038/s41467-022-32551-2 PMC 바로가기 [Article Type] Randomized Controlled Trial
How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies혈액암 환자와 세포 요법을 받는 환자의 COVID-19 치료 및 예방 방법Article Published on 2022-08-182022-09-11 Journal: Blood [Category] SARS, 변종, 임상, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration approach attenuate breakthrough infections Cell Cell therapy cell transplantation cellular therapy circulating circulating SARS-CoV-2 variants Clinical efficacy coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 in patient COVID-19 vaccine COVID-19 vaccines Drug-drug interactions Factors General population HCT Hematologic malignancy Hematopoietic cell transplantation higher risk Host Humoral response increased risk Infection morbidity morbidity and mortality Patient Postexposure Prophylaxis practicality Prevent progression recipient recipients SARS-CoV-2 Selection severe acute respiratory syndrome Coronavirus severe coronavirus disease severe COVID-19 Side effects therapeutic Therapies therapy treat Treatment virus [DOI] 10.1182/blood.2022016089 PMC 바로가기 [Article Type] Article
The Clinical Efficacy and Safety of Anti-Viral Agents for Non-Hospitalized Patients with COVID-19: A Systematic Review and Network Meta-Analysis of Randomized Controlled TrialsCOVID-19를 가진 비 병원 환자에 대한 항 바이러스 제제의 임상 효능 및 안전성 : 무작위 대조 시험의 체계적인 검토 및 네트워크 메타 분석Review Published on 2022-08-022022-08-31 Journal: Viruses [Category] meta-analysis, 임상, 치료제, [키워드] adverse event adverse events agent anti-viral agent anti-viral agents Anti-viral treatment best calculated clinical Clinical efficacy clinical setting Cochrane Library Controlled controlled trials COVID-19 death determined by Disease progression followed by Hospitalization increased risk Intravenous remdesivir investigated lowest molnupiravir network Network meta-analysis Nirmatrelvir nirmatrelvir plus ritonavir Patient patients with COVID-19 Placebo Probability Randomized controlled trial RCT RCTs receiving registry Remdesivir review risk risk of COVID-19 Ritonavir Safety searched shown significantly lower the WHO tolerable Treatment Web of Science WHO International Clinical Trials Registry Platform [DOI] 10.3390/v14081706 PMC 바로가기 [Article Type] Review
Network methods and design of randomized trials: Application to investigation of COVID-19 vaccination boosters네트워크 방법 및 무작위 시험 설계: 코로나19 백신 부스터 조사에 적용Article Published on 2022-08-012022-09-11 Journal: Clinical Trials (London, England) [Category] COVID19(2023년), SARS, 변종, 임상, 치료기술, 치료제, [키워드] Analysis antibody tests application approach approval arise booster Booster vaccine booster vaccines can be used Characteristics Clinical efficacy Cluster Combination consequence Contact COVID-19 COVID-19 vaccination detectability disease Effect Efficacy enrolled error evaluate the effect Evidence evidence of feasible flexible framework Guidance HIV HIV prevention incidence Infection infections infectiousness information intervention effect Intervention effects magnitude Molecular epidemiology motivation network network science neutralizing antibody novel populations Pragmatic provide random Randomized randomized trial randomized trials reduce cost Sample size SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 variants Spread Standard of care statistical Study design susceptibility Transmission Trial United Kingdom Vaccine vaccine efficacy variant [DOI] 10.1177/17407745221111818 PMC 바로가기 [Article Type] Article
The clinical efficacy and safety of mesenchymal stromal cells for patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials코로나19 환자를 위한 중간엽 기질세포의 임상적 효능 및 안전성: 무작위 대조 시험의 체계적인 검토 및 메타 분석Meta-Analysis Published on 2022-08-012022-09-11 Journal: Journal of infection and public health [Category] 신약개발, 임상, [키워드] 28-day mortality 95% CI addition adverse event adverse events AEs appear Clinical efficacy Clinical improvement Clinical outcome clinical outcomes ClinicalTrials Cochrane Library control group controls COVID-19 help IMPROVE investigated Mesenchymal stromal cell Mesenchymal stromal cells Meta-analysis Mortality mortality rate MSC MSCs OVID Patient patients patients with COVID-19 Placebo placebos Randomized controlled trial Randomized controlled trials RCT RCTs risk Safe SARS-CoV-2 searched serious AE serious AEs significantly higher significantly lower stromal cell stromal cells systematic review therapeutic option treat Treatment [DOI] 10.1016/j.jiph.2022.07.001 PMC 바로가기 [Article Type] Meta-Analysis
Oral Janus kinase inhibitors for treating hospitalized patients with COVID-19: An updated systematic review and meta-analysis of randomized controlled trialsResearch article Published on 2022-08-012022-10-05 Journal: Journal of microbiology, immunology, and infection [Category] 신약개발, 임상, 치료제, [키워드] 28-day mortality 95% CI 95% confidence interval addition adverse event Analysis article Clinical efficacy control group Controlled COVID-19 database exhibited hospitalized patient investigated Janus kinase inhibitor Janus kinase inhibitors mechanical ventilation Meta-analysis Mortality objective oral patients with COVID-19 Randomized controlled trial RCTs receiving reduce Result risk risk of death searched significantly significantly lower systematic review the study group tolerable Treatment with COVID-19 [DOI] 10.1016/j.jmii.2022.08.005 [Article Type] Research article
Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancerArticle Published on 2022-08-012023-07-09 Journal: European journal of cancer (Oxford, England : 1990 [Category] COVID19(2023년), [키워드] Cancer Clinical efficacy COVID-19 prevention SARS-CoV-2 Vaccines [DOI] 10.1016/j.ejca.2022.04.036 PMC 바로가기
RNA solutions to treat inborn errors of metabolism신진대사의 선천적 오류를 치료하기 위한 RNA 솔루션Review Published on 2022-08-012022-09-11 Journal: Molecular genetics and metabolism [Category] 유전자 메커니즘, [키워드] activating antisense Antisense oligonucleotides approved Biology Chemistry Clinical efficacy clinical trial clinical trials Clinical use COVID-19 drug drugs effective expression gene silencing help IEM include lncRNA mechanism mechanism of action messenger RNAs metabolism MicroRNAs molecules mRNA mutations New offer overcome Patient pharmacokinetic rare disease rare diseases Research RNA RNA interference RNA vaccine RNA vaccines RNAs siRNA splicing Stage suppress target tissues Therapeutic approach therapy tissues treat [DOI] 10.1016/j.ymgme.2022.07.006 PMC 바로가기 [Article Type] Review
Immunogenicity and clinical efficacy of anti-SARS-CoV-2 vaccination in patients with hematological malignancies: Results of a prospective cohort study of 365 patients혈액암 환자에서 항SARS-CoV-2 백신 접종의 면역원성과 임상 효능: 365명의 환자를 대상으로 한 전향적 코호트 연구 결과Article Published on 2022-08-012022-09-12 Journal: American journal of hematology [Category] MERS, 진단, [키워드] anti-SARS-CoV-2 vaccination Clinical efficacy hematological immunogenicity Patient prospective cohort study Result [DOI] 10.1002/ajh.26629 PMC 바로가기 [Article Type] Article
COVID-19 in patients with hematologic malignancy혈액암 환자의 코로나19Article Published on 2022-07-212022-09-11 Journal: Blood [Category] Coronavirus, COVID19(2023년), SARS, 변종, 치료제, [키워드] active immunization acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 advanced age Antibody Response Antiviral antiviral drug antiviral drugs Clinical efficacy contribute coronavirus COVID-19 COVID-19 in patient develop early treatment early treatment of COVID-19 hematologic Hematologic malignancy heterogeneity high risk illnesses immune response immune system Infectious disease malignancy MONITOR monoclonal antibodies monoclonal antibody mortality rate offered outcome pandemic Patient patients hospitalized Postexposure Prophylaxis predict Prevent reduced risk factor SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 vaccine SARS-CoV-2 vaccines severe acute respiratory syndrome Coronavirus severe COVID-19 significantly subtype symptomatic therapy Treatment vaccination Vaccine variants virus [DOI] 10.1182/blood.2021012251 PMC 바로가기 [Article Type] Article